Management of cardiac involvement associated with neuromuscular diseases: a scientific statement from the American Heart Association

B Feingold, WT Mahle, S Auerbach, P Clemens… - Circulation, 2017 - Am Heart Assoc
For many neuromuscular diseases (NMDs), cardiac disease represents a major cause of
morbidity and mortality. The management of cardiac disease in NMDs is made challenging …

Clinical features and molecular genetics of autosomal recessive cerebellar ataxias

BL Fogel, S Perlman - The Lancet Neurology, 2007 - thelancet.com
Among the hereditary ataxias, autosomal recessive spinocerebellar ataxias comprise a
diverse group of neurodegenerative disorders. Clinical phenotypes vary from predominantly …

Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study)

DR Lynch, MP Chin, MB Delatycki… - Annals of …, 2021 - Wiley Online Library
Objective Friedreich ataxia (FA) is a progressive genetic neurodegenerative disorder with no
approved treatment. Omaveloxolone, an Nrf2 activator, improves mitochondrial function …

Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia

DR Lynch, J Farmer, L Hauser, IA Blair… - Annals of clinical …, 2019 - Wiley Online Library
Objective Previous studies have demonstrated that suppression of Nrf2 in Friedreich ataxia
tissues contributes to excess oxidative stress, mitochondrial dysfunction, and reduced ATP …

Mortality in Friedreich ataxia

AY Tsou, EK Paulsen, SJ Lagedrost, SL Perlman… - Journal of the …, 2011 - Elsevier
Background Although cardiac dysfunction is widely accepted as the most common cause of
mortality in Friedreich ataxia (FRDA), no studies have evaluated this since the advent of …

Progression of Friedreich ataxia: quantitative characterization over 5 years

M Patel, CJ Isaacs, L Seyer, K Brigatti… - Annals of clinical …, 2016 - Wiley Online Library
Objective Friedreich ataxia (FRDA) is a progressive neurodegenerative disorder of adults
and children. This study analyzed neurological outcomes and changes to identify predictors …

Measuring Friedreich ataxia: complementary features of examination and performance measures

DR Lynch, JM Farmer, AY Tsou, S Perlman… - Neurology, 2006 - AAN Enterprises
Objective: To examine the potential validity of performance measures and examination-
based scales in Friedreich ataxia (FA) by examining their correlation with disease …

Current advances in gene therapies of genetic auditory neuropathy spectrum disorder

AR Saidia, J Ruel, A Bahloul, B Chaix, F Venail… - Journal of Clinical …, 2023 - mdpi.com
Auditory neuropathy spectrum disorder (ANSD) refers to a range of hearing impairments
characterized by an impaired transmission of sound from the cochlea to the brain. This …

Pharmacological therapeutics in Friedreich ataxia: the present state

C Strawser, K Schadt, L Hauser… - Expert review of …, 2017 - Taylor & Francis
Introduction: Friedreich ataxia (FRDA) is a progressive, inherited, neurodegenerative
disease for which there is currently no cure or approved treatment. FRDA is caused by …

Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design

LS Friedman, JM Farmer, S Perlman… - Movement …, 2010 - Wiley Online Library
Friedreich ataxia is an autosomal recessive neurodegenerative disorder characterized by
ataxia of all four limbs, dysarthria, and arreflexia. A variety of measures are currently used to …